Share on StockTwits

Uroplasty (NYSE:UPI) Director Kevin H. Roche acquired 10,000 shares of the stock in a transaction dated Wednesday, July 30th. The shares were purchased at an average price of $2.45 per share, for a total transaction of $24,500.00. Following the purchase, the director now directly owns 20,000 shares in the company, valued at approximately $49,000. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Uroplasty (NYSE:UPI) opened at 2.44 on Thursday. Uroplasty has a 1-year low of $2.21 and a 1-year high of $5.40. The stock’s 50-day moving average is $2.6 and its 200-day moving average is $3.40. The company’s market cap is $52.9 million.

Uroplasty (NYSE:UPI) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.05) by $0.05. On average, analysts predict that Uroplasty will post $-0.28 earnings per share for the current fiscal year.

Separately, analysts at Zacks downgraded shares of Uroplasty from a “neutral” rating to an “underperform” rating in a research note on Wednesday, July 16th. They now have a $2.50 price target on the stock.

Uroplasty, Inc is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.